Pharmaceutical

(Curcumin + doxorubicin) by Immix BioPharma for Colorectal Cancer: Likelihood of Approval

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Colorectal Cancer.

Dec 24, 2023 - 18:00
(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Colorectal Cancer.
Read the original article

Tags:

Previous Article

(Curcumin + doxorubicin) by Immix BioPharma for Metastatic Colorectal Cancer: Li...

Next Article

Enzalutamide by Pfizer for Peritoneal Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Liver disease researchers are hoping AI can improve their trial design

STAT+: Liver disease researchers are hoping AI can impr...

Apr 7, 2023

Mirum applies for extended use of PFIC therapy in Europe

Mirum applies for extended use of PFIC therapy in Europe

Apr 6, 2023

Which drugs are most likely to be approved in Somatic P...

Mar 28, 2024